CY1123761T1 - Τροποποιητες της πρωτεϊνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης - Google Patents

Τροποποιητες της πρωτεϊνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης

Info

Publication number
CY1123761T1
CY1123761T1 CY20211100074T CY211100074T CY1123761T1 CY 1123761 T1 CY1123761 T1 CY 1123761T1 CY 20211100074 T CY20211100074 T CY 20211100074T CY 211100074 T CY211100074 T CY 211100074T CY 1123761 T1 CY1123761 T1 CY 1123761T1
Authority
CY
Cyprus
Prior art keywords
methods
regulator protein
protein modifiers
conductivity regulator
fibro
Prior art date
Application number
CY20211100074T
Other languages
English (en)
Inventor
Robert J. Altenbach
Andrew Bogdan
Sylvain COUTY
Nicolas Desroy
Gregory A. Gfesser
Christopher Gaëtan HOUSSEMAN
Philip R. Kym
Bo Liu
Thi Thu Trang Mai
Karine Fabienne MALAGU
Olivier Laurent Picolet
Mathieu Rafaël PIZZONERO
Xenia B. Searle
Steven Emiel Van Der Plas
Xueqing Wang
Ming C. Yeung
Nuria Merayo Merayo
Original Assignee
AbbVie Overseas S.à r.l.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Overseas S.à r.l. filed Critical AbbVie Overseas S.à r.l.
Publication of CY1123761T1 publication Critical patent/CY1123761T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Sanitary Thin Papers (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Η εφεύρεση αποκαλύπτει ενώσεις του τύπου (Ι) όπου τα Α1, R1, R2, R3, R4 και n είναι όπως ορίζεται στο παρόν. Η παρούσα εφεύρεση αφορά ενώσεις και τη χρήση τους στην θεραπεία της κυστικής ίνωσης, μεθόδους για την παραγωγή τους, φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτές και μεθόδους θεραπείας της κυστικής ίνωσης δια χορήγησης μιας ένωσης της εφεύρεσης.
CY20211100074T 2017-09-14 2021-01-28 Τροποποιητες της πρωτεϊνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης CY1123761T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558430P 2017-09-14 2017-09-14
US201762608846P 2017-12-21 2017-12-21
PCT/IB2018/057020 WO2019053634A1 (en) 2017-09-14 2018-09-13 MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATORY PROTEIN OF CYSTIC FIBROSIS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CY1123761T1 true CY1123761T1 (el) 2022-05-27

Family

ID=63713961

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20211100074T CY1123761T1 (el) 2017-09-14 2021-01-28 Τροποποιητες της πρωτεϊνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης
CY20211100695T CY1124615T1 (el) 2017-09-14 2021-08-03 Τροποποιητες της πρωτεïνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης
CY20211100697T CY1124401T1 (el) 2017-09-14 2021-08-04 Τροποποιητες της πρωτεϊνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20211100695T CY1124615T1 (el) 2017-09-14 2021-08-03 Τροποποιητες της πρωτεïνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης
CY20211100697T CY1124401T1 (el) 2017-09-14 2021-08-04 Τροποποιητες της πρωτεϊνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης

Country Status (33)

Country Link
US (6) US10988454B2 (el)
EP (4) EP3736267B1 (el)
JP (4) JP7064072B2 (el)
KR (1) KR20200086661A (el)
CN (1) CN111954664A (el)
AU (1) AU2018332512A1 (el)
BR (1) BR112020005102A2 (el)
CA (1) CA3074945A1 (el)
CL (1) CL2020000664A1 (el)
CO (1) CO2020004249A2 (el)
CR (1) CR20200157A (el)
CY (3) CY1123761T1 (el)
DK (3) DK3736267T3 (el)
EC (1) ECSP20021913A (el)
ES (3) ES2856751T3 (el)
HR (3) HRP20210099T1 (el)
HU (3) HUE052873T2 (el)
IL (1) IL273163A (el)
LT (3) LT3681864T (el)
MA (1) MA50240B1 (el)
MD (3) MD3736267T2 (el)
MX (1) MX2020002806A (el)
PE (1) PE20210140A1 (el)
PH (1) PH12020500509A1 (el)
PL (3) PL3681864T3 (el)
PT (3) PT3736270T (el)
RS (3) RS62190B1 (el)
RU (1) RU2020113350A (el)
SG (1) SG11202002101RA (el)
SI (3) SI3681864T1 (el)
UA (1) UA125541C2 (el)
WO (1) WO2019053634A1 (el)
ZA (1) ZA202002363B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ768373A (en) 2014-10-06 2024-03-22 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US10570115B2 (en) 2016-09-30 2020-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2017371200B2 (en) 2016-12-09 2021-05-06 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
RS62818B1 (sr) 2017-10-18 2022-02-28 Incyte Corp Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11066417B2 (en) 2018-02-15 2021-07-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP2022514253A (ja) * 2018-12-18 2022-02-10 ノバルティス アーゲー Ｎ－（ピリジン－２－イルスルホニル）シクロプロパンカルボキサミド誘導体及びｃｆｔｒ媒介疾患の処置におけるその使用
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
WO2022150174A1 (en) * 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220213041A1 (en) * 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB602426A (en) * 1945-10-24 1948-05-26 Geigy Ag J R Manufacture of aromatic acyl-sulphonamides
CN1505613A (zh) * 2000-10-10 2004-06-16 ʷ��˿�������ȳ�ķ���޹�˾ 取代的吲哚、含这类吲哚的药物组合物及它们作为PPAR-γ结合剂的用途
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
CN101006076B (zh) 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
NZ576642A (en) 2006-11-03 2011-11-25 Vertex Pharma Azaindole derivatives as cftr modulators
ES2548292T3 (es) 2007-05-25 2015-10-15 Vertex Pharmaceuticals Incorporated Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
PE20090995A1 (es) * 2007-08-29 2009-08-03 Schering Corp Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
EP2222660B1 (en) * 2007-11-16 2014-03-26 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
TWI439462B (zh) 2007-12-10 2014-06-01 Novartis Ag 作為ｅｎａｃ阻抑劑之螺環胍化合物
CN101925603B (zh) 2007-12-13 2013-12-04 沃泰克斯药物股份有限公司 囊性纤维化跨膜通道调节因子的调节剂
EP2279029A2 (en) 2008-03-25 2011-02-02 The Regents of the University of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
PL2358680T3 (pl) 2008-10-23 2013-08-30 Vertex Pharma Stałe postacie N-(4-(7-azabicyklo[2.2.1]heptan-7-ylo)-2-(trifluorometylo)fenylo)-4-okso-5-(trifluorometylo)-1,4-dihydrochinolino-3-karboksyamidu
AU2008363828B2 (en) 2008-11-06 2016-09-08 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
EP2421368A4 (en) * 2009-04-20 2013-01-09 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
IN2013MN00501A (el) 2010-10-08 2015-05-29 N30 Pharmaceuticals Inc
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013043720A1 (en) 2011-09-20 2013-03-28 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
MX368263B (es) 2013-05-07 2019-09-26 Galapagos Nv Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
CA2919776A1 (en) 2013-08-08 2015-02-12 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
CN103484818A (zh) 2013-09-25 2014-01-01 京东方科技集团股份有限公司 蒸镀方法、蒸镀装置和发光器件
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
KR102132215B1 (ko) 2014-04-03 2020-07-09 삼성전자주식회사 자기 터널 접합 구조물 형성 방법 및 이를 이용한 자기 메모리 소자의 제조 방법
NZ768373A (en) 2014-10-06 2024-03-22 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CN107427490A (zh) 2014-10-31 2017-12-01 艾伯维公司 取代的四氢吡喃和使用方法
CN107405337B (zh) 2014-10-31 2021-02-09 艾伯维公司 取代的色满和使用方法
KR20180029204A (ko) 2015-06-02 2018-03-20 애브비 에스.에이.알.엘. 치환된 피리딘 및 사용 방법
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
CA3001096A1 (en) 2015-10-09 2017-04-13 Abbvie S.A.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Also Published As

Publication number Publication date
LT3681864T (lt) 2021-02-25
EP3865474A1 (en) 2021-08-18
MA50240A (fr) 2020-07-22
CY1124615T1 (el) 2022-07-22
IL273163A (en) 2020-04-30
DK3736270T3 (da) 2021-08-09
RS62190B1 (sr) 2021-08-31
JP2022062093A (ja) 2022-04-19
EP3736267A1 (en) 2020-11-11
JP7064073B2 (ja) 2022-05-10
PL3736267T3 (pl) 2021-11-15
US20200277275A1 (en) 2020-09-03
HUE052873T2 (hu) 2021-05-28
US10844041B2 (en) 2020-11-24
EP3736270B1 (en) 2021-05-05
MA50240B1 (fr) 2021-03-31
JP2022000461A (ja) 2022-01-04
US20200277274A1 (en) 2020-09-03
ES2887449T3 (es) 2021-12-22
US20190077784A1 (en) 2019-03-14
US10844042B2 (en) 2020-11-24
US10988454B2 (en) 2021-04-27
PL3681864T4 (pl) 2021-05-17
CA3074945A1 (en) 2019-03-21
SI3681864T1 (sl) 2021-08-31
JP7064074B2 (ja) 2022-05-10
BR112020005102A2 (pt) 2020-09-24
EP3736270A1 (en) 2020-11-11
US20210238159A1 (en) 2021-08-05
EP3736267B1 (en) 2021-05-05
DK3736267T3 (da) 2021-08-09
CR20200157A (es) 2021-02-16
ECSP20021913A (es) 2020-05-29
SI3736267T1 (sl) 2021-09-30
PT3736267T (pt) 2021-08-10
EP3681864B1 (en) 2020-10-28
SG11202002101RA (en) 2020-04-29
US20200277273A1 (en) 2020-09-03
MX2020002806A (es) 2020-10-12
MD3736270T2 (ro) 2021-11-30
ZA202002363B (en) 2021-06-30
PE20210140A1 (es) 2021-01-21
DK3681864T3 (da) 2021-01-25
PL3681864T3 (pl) 2021-05-17
RU2020113350A3 (el) 2022-04-14
UA125541C2 (uk) 2022-04-13
US10981890B2 (en) 2021-04-20
HUE055241T2 (hu) 2021-11-29
MD3736267T2 (ro) 2021-11-30
ES2881881T3 (es) 2021-11-30
LT3736267T (lt) 2021-08-25
HRP20210099T1 (hr) 2021-03-05
PH12020500509A1 (en) 2021-05-31
AU2018332512A1 (en) 2020-04-23
PT3681864T (pt) 2021-02-25
HRP20211198T1 (hr) 2021-10-29
CL2020000664A1 (es) 2020-11-06
HRP20211200T1 (hr) 2021-10-29
PT3736270T (pt) 2021-08-10
JP2020534360A (ja) 2020-11-26
LT3736270T (lt) 2021-08-25
RS61899B1 (sr) 2021-06-30
EP3681864A1 (en) 2020-07-22
CN111954664A (zh) 2020-11-17
JP7064072B2 (ja) 2022-05-10
HUE055050T2 (hu) 2021-10-28
US20200277276A1 (en) 2020-09-03
US10829473B2 (en) 2020-11-10
CY1124401T1 (el) 2022-07-22
KR20200086661A (ko) 2020-07-17
CO2020004249A2 (es) 2020-08-31
RS62185B1 (sr) 2021-08-31
MD3681864T2 (ro) 2021-05-31
ES2856751T3 (es) 2021-09-28
PL3736270T3 (pl) 2021-11-15
JP2022000460A (ja) 2022-01-04
SI3736270T1 (sl) 2021-09-30
RU2020113350A (ru) 2021-10-15
WO2019053634A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
CY1123761T1 (el) Τροποποιητες της πρωτεϊνης ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης και μεθοδοι χρησης
CY1124031T1 (el) Ετεροαρυλ υποκατεστημενες πυριδινες και μεθοδοι χρησης
CY1121027T1 (el) Θeieno[2,3-c]πypania ως διαμορφωτες cftr
CY1121030T1 (el) Προφαρμακα πυριδονο αμιδιων χρησιμα ως διαμορφωτες διαυλων νατριου
CY1123186T1 (el) Μακροκυκλικοι mcl1 αναστολεις για τη θεραπευτικη αντιμετωπιση του καρκινου
MX2019004019A (es) Pirrolidinas sustituidas como moduladores cftr.
PH12017502201A1 (en) Substituted pyridines and method of use
MX2019004018A (es) Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica.
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1122870T1 (el) Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
MX368263B (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
CY1110115T1 (el) Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1126082T1 (el) Τροποποιητες toy trex1
CY1111631T1 (el) Παραγωγα των 7-αλκυνυλο-1,8- ναφθυριδονων, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1116542T1 (el) Νεα παραγωγα (συμπυκνωμενης ετεροκυκλο-πιπεριδινης)-(πιπεραζινυλ)-1-αλκανονης ή (συμπυκνωμενης ετεροκυκλο-πυρρολιδινης)-(πιπεραζινυλ)-1-αλκανονης, και χρηση αυτων ως αναστολεων p75
CY1126039T1 (el) Ενωσεις και συνθεσεις ουριας ως αναστολεις της ατρ-ασης smarca2/brm
CY1121154T1 (el) Νεα παραγωγα φωσφινανιου και αζαφωσφινανιου, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1120242T1 (el) Παραγωγο δισπειροπυρρολιδινης